**Table S1 : Subject Demographics**

|  |  |  |
| --- | --- | --- |
| **Variable** | **RHA1-M Study: Perioral Rhytids treatment**  **(N=30)** | **RHA4-M Study: Nasolabial Folds treatment**  **(N=30)** |
| **Age, years** | 64.3 ± 8.2 | 57.0 ± 9.7 |
| **BMI, kg/m2** | 26.3 ± 4.6 | 28.1 ± 4.5 |
| **Female, n (%)** | 30 (100%) | 27 (90.0%) |
| **Fitzpatrick Skin Phototype** | | |
| I-III | 23 (76.7%) | 19 (63.3%) |
| IV-VI | 7 (23.3%) | 11 (36.7%) |

**Table S2 : Treatment-Related Adverse Events**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Perioral Rhytids treatment: RHA1 versus RHA1-M (N=30)** | | | | |
| **Treatment-Related AE** | | **RHA1** | **RHA1-M** | **All** |
| **Any TRAE** | **Subjects** | **3 (10.0%)** | **4 (13.3%)** | **4 (13.3%)** |
| **Events** | **4** | **5** | **9** |
| Injection site induration | Subjects | 2 (6.7%) | 2 (6.7%) | 2 (6.7%) |
| Events | 2 | 2 | 4 |
| Injection site pain | Subjects | 1 (3.3%) | 1 (3.3%) | 1 (3.3%) |
| Events | 1 | 1 | 2 |
| Injection site mass | Subjects | 0 (0.0%) | 1 (3.3%) | 1 (3.3%) |
| Events | 0 | 1 | 1 |
| Needle marks | Subjects | 1 (3.3%) | 1 (3.3%) | 1 (3.3%) |
| Events | 1 | 1 | 2 |
| **Nasolabial Folds treatment: RHA4 versus RHA4-M (N=30)** | | | | |
| **Treatment-Related AE** | | **RHA4** | **RHA4-M** | **All** |
| **Any TRAE** | **Subjects** | **4 (13.3%)** | **5 (16.7%)** | **5 (16.7%)** |
| **Events** | **5** | **6** | **11** |
| Injection site induration | Subjects | 4 (13.3%) | 3 (10.0%) | 4 (13.3%) |
| Events | 4 | 3 | 7 |
| Injection site mass | Subjects | 0 (0.0%) | 1 (3.3%) | 1 (3.3%) |
| Events | 0 | 1 | 1 |
| Injection site pruritus | Subjects | 1 (3.3%) | 1 (3.3%) | 1 (3.3%) |
| Events | 1 | 1 | 2 |
| Paresthesia | Subjects | 0 (0.0%) | 1 (3.3%) | 1 (3.3%) |
| Events | 0 | 1 | 1 |